Cargando…

The Biological Substrate of the Motoric Cognitive Risk Syndrome: A Pilot Study Using Amyloid-/Tau-PET and MR Imaging

We conducted a cross-sectional pilot study to explore the biological substrate of the Motoric Cognitive Risk (MCR) syndrome in a Memory Clinic cohort, using a multimodal imaging approach. Twenty participants were recruited and classified as MCR+/−. Amyloid- and tau-PET uptakes, temporal atrophy, whi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bommarito, Giulia, Garibotto, Valentina, Frisoni, Giovanni B., Ribaldi, Federica, Stampacchia, Sara, Assal, Frédéric, Armand, Stéphane, Allali, Gilles, Griffa, Alessandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2022
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277684/ https://www.ncbi.nlm.nih.gov/pubmed/35491777 http://dx.doi.org/10.3233/JAD-215461

Ejemplares similares

Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison
por: Altomare, Daniele, et al.
Publicado: (2021)

CSF tap test in idiopathic normal pressure hydrocephalus: still a necessary prognostic test?
por: Griffa, Alessandra, et al.
Publicado: (2022)

Dynamic functional networks in idiopathic normal pressure hydrocephalus: Alterations and reversibility by CSF tap test
por: Griffa, Alessandra, et al.
Publicado: (2020)

Unsupervised [(18)F]Flortaucipir cutoffs for tau positivity and staging in Alzheimer’s disease
por: Quattrini, Giulia, et al.
Publicado: (2023)

The Clinical Use of Alzheimer’s Disease Biomarkers in Patients with Mild Cognitive Impairment: A European Alzheimer’s Disease Consortium Survey
por: Caprioglio, Camilla, et al.
Publicado: (2022)

Normal pressure hydrocephalus and CSF tap test response: the gait phenotype matters
por: Morel, Eric, et al.
Publicado: (2020)

Topographical Heterogeneity of Alzheimer’s Disease Based on MR Imaging, Tau PET, and Amyloid PET
por: Jeon, Seun, et al.
Publicado: (2019)

The taxonomy of subjective cognitive decline: proposal and first clinical evidence from the Geneva memory clinic cohort
por: Ribaldi, Federica, et al.
Publicado: (2023)

Prognostic value of imaging-based ATN profiles in a memory clinic cohort
por: Peretti, Débora E., et al.
Publicado: (2023)

Dual-task related gait changes after CSF tapping: a new way to identify idiopathic normal pressure hydrocephalus
por: Allali, Gilles, et al.
Publicado: (2013)

C-reactive protein and white matter microstructural changes in COVID-19 patients with encephalopathy
por: Rhally, Alexandra, et al.
Publicado: (2021)

Predicting amyloid PET and tau PET stages with plasma biomarkers
por: Jack, Clifford R, et al.
Publicado: (2023)

2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Leuzy, A., et al.
Publicado: (2021)

ATN profile classification across two independent prospective cohorts
por: Peretti, Débora E., et al.
Publicado: (2023)

Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives
por: Cotta Ramusino, Matteo, et al.
Publicado: (2021)

Plasma biomarkers for Alzheimer’s disease: a field-test in a memory clinic
por: Altomare, Daniele, et al.
Publicado: (2023)

Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals
por: Groot, Colin, et al.
Publicado: (2022)

The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers
por: Ashton, N. J., et al.
Publicado: (2021)

Amyloid- and tau-PET imaging in a familial prion kindred
por: Jones, David T., et al.
Publicado: (2018)

Amyloid duration is associated with preclinical cognitive decline and tau PET
por: Koscik, Rebecca L., et al.
Publicado: (2020)

Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Chiotis, Konstantinos, et al.
Publicado: (2021)

Qualitative and Quantitative Evaluation of Blob-Based Time-of-Flight PET Image Reconstruction in Hybrid Brain PET/MR Imaging
por: Leemans, Eva L., et al.
Publicado: (2015)

Comprehensive characterization of elevated tau PET signal in the absence of amyloid-beta
por: Weigand, Alexandra J, et al.
Publicado: (2022)

Mapping the association between tau-PET and Aβ-amyloid-PET using deep learning
por: Ruwanpathirana, Gihan P., et al.
Publicado: (2022)

Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Bischof, Gérard N, et al.
Publicado: (2021)

Gait analysis in demented subjects: Interests and perspectives
por: Beauchet, Olivier, et al.
Publicado: (2008)

FDG-PET hypermetabolism is associated with higher tau-PET in mild cognitive impairment at low amyloid-PET levels
por: Rubinski, Anna, et al.
Publicado: (2020)

Amyloid burden quantification depends on PET and MR image processing methodology
por: Kolinger, Guilherme D., et al.
Publicado: (2021)

Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status
por: Shen, Xue-Ning, et al.
Publicado: (2021)

Amyloid and tau PET in cerebral amyloid angiopathy-related inflammation two case reports and literature review
por: Yang, Jhih-Yong, et al.
Publicado: (2023)

COVID-19 associated stroke and cerebral endotheliitis
por: Stancu, Patrick, et al.
Publicado: (2021)

Tau-PET uptake: Regional variation in average SUVR and impact of amyloid deposition
por: Vemuri, Prashanthi, et al.
Publicado: (2016)

Is tau in the absence of amyloid on the Alzheimer’s continuum?: A study of discordant PET positivity
por: Weigand, Alexandra J, et al.
Publicado: (2019)

Correction to: Comprehensive characterization of elevated tau PET signal in the absence of amyloid-beta
Publicado: (2023)

PET amyloid in normal aging: direct comparison of visual and automatic processing methods
por: Haller, Sven, et al.
Publicado: (2020)

Feeling of presence in dementia with Lewy bodies is related to reduced left frontoparietal metabolism
por: Nicastro, Nicolas, et al.
Publicado: (2018)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
por: Mattsson‐Carlgren, Niklas, et al.
Publicado: (2021)

Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum
por: Doré, Vincent, et al.
Publicado: (2022)

A Survey of FDG- and Amyloid-PET Imaging in Dementia and GRADE Analysis
por: Daniela, Perani, et al.
Publicado: (2014)

Regional binding of tau and amyloid PET tracers in Down syndrome autopsy brain tissue
por: Lemoine, L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9nrfppira5rsvfoj5b4rs2roo0